Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962367 | 1.00 | PTGS2 (0.40) | PTGS2NOD2NOD1PTGDR2AKR1C3 | |
| SCHEMBL1960804 | 0.86 | NOD2 (0.35) | NOD2NOD1PTGDR2 | |
| SCHEMBL1960805 | 0.86 | NOD2 (0.35) | NOD2NOD1PTGDR2 | |
| SCHEMBL1961492 | 0.86 | PTGS2 (0.40) | PTGS2NOD2NOD1 | |
| SCHEMBL1961490 | 0.86 | PTGS2 (0.40) | PTGS2NOD2NOD1 | |
| SCHEMBL1962772 | 0.84 | PTGS2 (0.37) | PTGS2AKR1C3 | |
| SCHEMBL1962775 | 0.84 | PTGS2 (0.37) | PTGS2AKR1C3 | |
| SCHEMBL1961002 | 0.83 | NOD2 (0.35) | NOD2NOD1PTGDR2 | |
| SCHEMBL1961001 | 0.83 | NOD2 (0.35) | NOD2NOD1PTGDR2 | |
| SCHEMBL1961603 | 0.82 | GCK (0.39) | PTGS2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PTGS2 1580/4885NOD2 4541/4885NOD1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.